-
Comparative Effectiveness Research with Average Hazard for Censored Time-to-Event Outcomes: A Numerical Study
Authors:
Hong Xiong,
Jean Connors,
Deb Schrag,
Hajime Uno
Abstract:
The average hazard (AH), recently introduced by Uno and Horiguchi, represents a novel summary metric of event time distributions, conceptualized as the general censoring-free average person-time incidence rate on a given time window, $[0,τ].$ This metric is calculated as the ratio of the cumulative incidence probability at $τ$ to the restricted mean survival time at $τ$ and can be estimated throug…
▽ More
The average hazard (AH), recently introduced by Uno and Horiguchi, represents a novel summary metric of event time distributions, conceptualized as the general censoring-free average person-time incidence rate on a given time window, $[0,τ].$ This metric is calculated as the ratio of the cumulative incidence probability at $τ$ to the restricted mean survival time at $τ$ and can be estimated through non-parametric methods. The AH's difference and ratio present viable alternatives to the traditional Cox's hazard ratio for quantifying the treatment effect on time-to-event outcomes in comparative clinical studies. While the methodology for evaluating the difference and ratio of AH in randomized clinical trials has been previously proposed, the application of the AH-based approach in general comparative effectiveness research (CER), where interventions are not randomly allocated, remains underdiscussed. This paper aims to introduce several approaches for applying the AH in general CER, thereby extending its utility beyond randomized trial settings to observational studies where treatment assignment is non-random.
△ Less
Submitted 30 June, 2024;
originally announced July 2024.
-
Measuring performance for end-of-life care
Authors:
Sebastien Haneuse,
Deborah Schrag,
Francesca Dominici,
Sharon-Lise Normand,
Kyu Ha Lee
Abstract:
Although not without controversy, readmission is entrenched as a hospital quality metric, with statistical analyses generally based on fitting a logistic-Normal generalized linear mixed model. Such analyses, however, ignore death as a competing risk, although doing so for clinical conditions with high mortality can have profound effects; a hospitals seemingly good performance for readmission may b…
▽ More
Although not without controversy, readmission is entrenched as a hospital quality metric, with statistical analyses generally based on fitting a logistic-Normal generalized linear mixed model. Such analyses, however, ignore death as a competing risk, although doing so for clinical conditions with high mortality can have profound effects; a hospitals seemingly good performance for readmission may be an artifact of it having poor performance for mortality. In this paper we propose novel multivariate hospital-level performance measures for readmission and mortality, that derive from framing the analysis as one of cluster-correlated semi-competing risks data. We also consider a number of profiling-related goals, including the identification of extreme performers and a bivariate classification of whether the hospital has higher-/lower-than-expected readmission and mortality rates, via a Bayesian decision-theoretic approach that characterizes hospitals on the basis of minimizing the posterior expected loss for an appropriate loss function. In some settings, particularly if the number of hospitals is large, the computational burden may be prohibitive. To resolve this, we propose a series of analysis strategies that will be useful in practice. Throughout the methods are illustrated with data from CMS on N=17,685 patients diagnosed with pancreatic cancer between 2000-2012 at one of J=264 hospitals in California.
△ Less
Submitted 18 May, 2021;
originally announced May 2021.
-
Hierarchical models for semi-competing risks data with application to quality of end-of-life care for pancreatic cancer
Authors:
Kyu Ha Lee,
Francesca Dominici,
Deborah Schrag,
Sebastien Haneuse
Abstract:
Readmission following discharge from an initial hospitalization is a key marker of quality of health care in the United States. For the most part, readmission has been used to study quality of care for patients with acute health conditions, such as pneumonia and heart failure, with analyses typically based on a logistic-Normal generalized linear mixed model. Applying this model to the study readmi…
▽ More
Readmission following discharge from an initial hospitalization is a key marker of quality of health care in the United States. For the most part, readmission has been used to study quality of care for patients with acute health conditions, such as pneumonia and heart failure, with analyses typically based on a logistic-Normal generalized linear mixed model. Applying this model to the study readmission among patients with increasingly prevalent advanced health conditions such as pancreatic cancer is problematic, however, because it ignores death as a competing risk. A more appropriate analysis is to imbed such studies within the semi-competing risks framework. To our knowledge, however, no comprehensive statistical methods have been developed for cluster-correlated semi-competing risks data. In this paper we propose a novel hierarchical modeling framework for the analysis of cluster-correlated semi-competing risks data. The framework permits parametric or non-parametric specifications for a range of model components, including baseline hazard functions and distributions for key random effects, giving analysts substantial flexibility as they consider their own analyses. Estimation and inference is performed within the Bayesian paradigm since it facilitates the straightforward characterization of (posterior) uncertainty for all model parameters including hospital-specific random effects. The proposed framework is used to study the risk of readmission among 5,298 Medicare beneficiaries diagnosed with pancreatic cancer at 112 hospitals in the six New England states between 2000-2009, specifically to investigate the role of patient-level risk factors and to characterize variation in risk across hospitals that is not explained by differences in patient case-mix.
△ Less
Submitted 5 August, 2015; v1 submitted 2 February, 2015;
originally announced February 2015.
